Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16417853 | 0.81 | GAA (0.41) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL2623474 | 0.77 | — | — | |
| SCHEMBL21697868 | 0.75 | — | — | |
| SCHEMBL21179495 | 0.75 | — | — | |
| SCHEMBL24565069 | 0.74 | GAA (0.36) | GAAL3MBTL1 | |
| SCHEMBL5465237 | 0.73 | GAA (0.39) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL13811825 | 0.73 | GAA (0.39) | GAAL3MBTL1 | |
| SCHEMBL21163316 | 0.72 | GAA (0.46) | GAAL3MBTL1KDM4EALDH1A1ALOX15 | |
| SCHEMBL679108 | 0.71 | GAA (0.52) | GAAL3MBTL1 | |
| SCHEMBL14012545 | 0.71 | CYP2D6 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338348-A1 | RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME | TROCAR PHARMA INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220202800-A1 | Method of Treatment of Organic Acidemias and Other Mitochondria Defects or Deficiencies | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-06-30 | — | — | US | disclosed |
| US-11207343-B2 | Compositions and therapeutic methods | AYUVIS RESEARCH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-20200317730-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-10-08 | — | — | US | disclosed |
| US-10414729-B2 | Site-specific dynamic nuclear polarization NMR agents | NORTH CAROLINA STATE UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-9732105-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170029377-A1 | SITE-SPECIFIC DYNAMIC NUCLEAR POLARIZATION NMR AGENTS | UNITED STATES DEPARTMENT OF ENERGY | 2017-02-02 | — | — | US | disclosed |
| US-20170029377-A1 | SITE-SPECIFIC DYNAMIC NUCLEAR POLARIZATION NMR AGENTS | UNITED STATES DEPARTMENT OF ENERGY | 2017-02-02 | — | — | US | disclosed |
| US-20160218354-A1 | Hybrid Electrode For Non-Aqueous Electrolyte Secondary Battery | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2016-07-28 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-06-26 | — | — | US | disclosed |
| US-20070197477-A1 | PHOSPHONIUM SALTS DERIVATIVES | VALORISATION-RECHERECHE (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | GAA 2877/4885L3MBTL1 2210/4885KDM4E 1626/4885 |
| US-11207343-B2 | Compositions and therapeutic methods | RB1, TNF, FLT1 | GAA 1224/4885L3MBTL1 3218/4885KDM4E 2476/4885 |
| US-20230338348-A1 | RENIN-ANGIOTENSIN SYSTEM (RAS) MODULATORS FOR TREATMENT OF VIRAL INFECTIONS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS OF TREATING USING THE SAME | ACE2, ACE, AGTR1 | GAA 4192/4885L3MBTL1 4560/4885KDM4E 2744/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | GAA 254/4885L3MBTL1 4453/4885KDM4E 2403/4885 |
| US-20070197477-A1 | PHOSPHONIUM SALTS DERIVATIVES | PI4K2A, PIP4K2A, PI4K2B | GAA 1914/4885L3MBTL1 2488/4885KDM4E 3198/4885 |
| US-20200317730-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | GAA 2457/4885L3MBTL1 1197/4885KDM4E 2171/4885 |
| US-20170029377-A1 | SITE-SPECIFIC DYNAMIC NUCLEAR POLARIZATION NMR AGENTS | ADAR, HNRNPR, ANP32A | GAA 3999/4885L3MBTL1 1321/4885KDM4E 3842/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | GAA 1484/4885L3MBTL1 3468/4885KDM4E 3076/4885 |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | ADRA2B, ADRA1B, ADRB1 | GAA 2496/4885L3MBTL1 3325/4885KDM4E 4245/4885 |
| US-10414729-B2 | Site-specific dynamic nuclear polarization NMR agents | ADAR, HNRNPR, ANP32A | GAA 3999/4885L3MBTL1 1321/4885KDM4E 3842/4885 |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | GAA 2457/4885L3MBTL1 1197/4885KDM4E 2171/4885 |
| US-20220202800-A1 | Method of Treatment of Organic Acidemias and Other Mitochondria Defects or Deficiencies | OAT, OTC, HOGA1 | GAA 253/4885L3MBTL1 868/4885KDM4E 4188/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | GAA 4734/4885L3MBTL1 3969/4885KDM4E 2235/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | GAA 762/4885L3MBTL1 4289/4885KDM4E 2614/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | GAA 1190/4885L3MBTL1 3552/4885KDM4E 1236/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | GAA 1104/4885L3MBTL1 4408/4885KDM4E 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.